Acquiring Company
Incyte Corporation
Acquired Company
Vega Therapeutics
WilmingtonBiotechnologyTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Incyte has entered into a definitive agreement to acquire Vega Therapeutics for $1.25 billion, with potential additional payments of up to $750 million. The acquisition aims to enhance Incyte's hematology portfolio with VGA039, a monoclonal antibody in Phase 3 development. The deal has received approval from both companies' Boards of Directors and is subject to standard closing conditions.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
- Gilead Sciences to acquire MacroGenics for $1.7B, $1.7B (May 19, 2026)
- Vertex to acquire Crinetics Pharmaceuticals for $10B, $10B (July 6, 2026)
- Selecta Biosciences merges with Cartesian Therapeutics (May 17, 2026)
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Eli Lilly to acquire Ajax Therapeutics for $2.3B, $2.3B (April 27, 2026)
Who to call at Incyte Corporation, and when
When Incyte Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Incyte Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Incyte Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Incyte Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Incyte Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Vega Therapeutics?
Vega Therapeutics was acquired by Incyte Corporation, based in Wilmington. The deal was reported on June 8, 2026. Incyte is a global biopharmaceutical company focused on advancing innovative medicines through deep scientific expertise and a patient-centered approach. Incyte Corporation is publicly traded (INCY) and operates in Biotechnology.
When did Incyte Corporation acquire Vega Therapeutics?
Incyte Corporation's acquisition of Vega Therapeutics was reported on June 8, 2026. Incyte has entered into a definitive agreement to acquire Vega Therapeutics for $1.25 billion, with potential additional payments of up to $750 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Vega Therapeutics do?
Vega Therapeutics, Inc. is a wholly owned subsidiary of Star Therapeutics, LLC. It focuses on developing therapeutic solutions for bleeding disorders, particularly targeting Protein S for disease treatment. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.